Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Tick cysteine protease inhibitors suppress immune responses in mannan-induced psoriasis-like inflammation

H. Wu, MA. Jmel, J. Chai, M. Tian, X. Xu, Y. Hui, KS. Nandakumar, M. Kotsyfakis

. 2024 ; 15 (-) : 1344878. [pub] 20240220

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007084

Protease inhibitors regulate various biological processes and prevent host tissue/organ damage. Specific inhibition/regulation of proteases is clinically valuable for treating several diseases. Psoriasis affects the skin in the limbs and scalp of the body, and the contribution of cysteine and serine proteases to the development of skin inflammation is well documented. Cysteine protease inhibitors from ticks have high specificity, selectivity, and affinity to their target proteases and are efficient immunomodulators. However, their potential therapeutic effect on psoriasis pathogenesis remains to be determined. Therefore, we tested four tick cystatins (Sialostatin L, Sialostatin L2, Iristatin, and Mialostatin) in the recently developed, innate immunity-dependent mannan-induced psoriasis model. We explored the effects of protease inhibitors on clinical symptoms and histological features. In addition, the number and percentage of immune cells (dendritic cells, neutrophils, macrophages, and γδT cells) by flow cytometry, immunofluorescence/immunohistochemistry and, the expression of pro-inflammatory cytokines (TNF-a, IL-6, IL-22, IL-23, and IL-17 family) by qPCR were analyzed using skin, spleen, and lymph node samples. Tick protease inhibitors have significantly decreased psoriasis symptoms and disease manifestations but had differential effects on inflammatory responses and immune cell populations, suggesting different modes of action of these inhibitors on psoriasis-like inflammation. Thus, our study demonstrates, for the first time, the usefulness of tick-derived protease inhibitors for treating skin inflammation in patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007084
003      
CZ-PrNML
005      
20240423155721.0
007      
ta
008      
240412e20240220sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2024.1344878 $2 doi
035    __
$a (PubMed)38444844
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Wu, Huimei $u Department of Pharmacy, The Eighth Affiliated City Hospital of Guangzhou Medical University, The Eighth People's Hospital of Guangzhou, Guangzhou, China $u Karolinska Institute United Medical Inflammation Center, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
245    10
$a Tick cysteine protease inhibitors suppress immune responses in mannan-induced psoriasis-like inflammation / $c H. Wu, MA. Jmel, J. Chai, M. Tian, X. Xu, Y. Hui, KS. Nandakumar, M. Kotsyfakis
520    9_
$a Protease inhibitors regulate various biological processes and prevent host tissue/organ damage. Specific inhibition/regulation of proteases is clinically valuable for treating several diseases. Psoriasis affects the skin in the limbs and scalp of the body, and the contribution of cysteine and serine proteases to the development of skin inflammation is well documented. Cysteine protease inhibitors from ticks have high specificity, selectivity, and affinity to their target proteases and are efficient immunomodulators. However, their potential therapeutic effect on psoriasis pathogenesis remains to be determined. Therefore, we tested four tick cystatins (Sialostatin L, Sialostatin L2, Iristatin, and Mialostatin) in the recently developed, innate immunity-dependent mannan-induced psoriasis model. We explored the effects of protease inhibitors on clinical symptoms and histological features. In addition, the number and percentage of immune cells (dendritic cells, neutrophils, macrophages, and γδT cells) by flow cytometry, immunofluorescence/immunohistochemistry and, the expression of pro-inflammatory cytokines (TNF-a, IL-6, IL-22, IL-23, and IL-17 family) by qPCR were analyzed using skin, spleen, and lymph node samples. Tick protease inhibitors have significantly decreased psoriasis symptoms and disease manifestations but had differential effects on inflammatory responses and immune cell populations, suggesting different modes of action of these inhibitors on psoriasis-like inflammation. Thus, our study demonstrates, for the first time, the usefulness of tick-derived protease inhibitors for treating skin inflammation in patients.
650    _2
$a lidé $7 D006801
650    _2
$a inhibitory cysteinových proteinas $7 D015853
650    _2
$a mannany $7 D008351
650    12
$a psoriáza $x chemicky indukované $x farmakoterapie $7 D011565
650    _2
$a zánět $x farmakoterapie $7 D007249
650    12
$a dermatitida $7 D003872
650    _2
$a inhibitory proteas $7 D011480
650    _2
$a přirozená imunita $7 D007113
650    _2
$a endopeptidasy $7 D010450
650    _2
$a proteasy $7 D010447
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Jmel, Mohamed Amine $u Institute of Parasitology, Biology Centre, Czech Academy of Sciences, České Budějovice, Czechia
700    1_
$a Chai, Jinwei $u Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
700    1_
$a Tian, Maolin $u Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
700    1_
$a Xu, Xueqing $u Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China $u Department of Pulmonary and Critical Care Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China
700    1_
$a Hui, Yuan $u Department of Endocrinology, Fifth Affiliated Hospital, Southern Medical University, Guangzhou, China
700    1_
$a Nandakumar, Kutty Selva $u Karolinska Institute United Medical Inflammation Center, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China $u Department of Environmental and Biosciences, School of Business, Innovation and Sustainability, Halmstad University, Halmstad, Sweden
700    1_
$a Kotsyfakis, Michail $u Institute of Parasitology, Biology Centre, Czech Academy of Sciences, České Budějovice, Czechia $u Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, Heraklion, Crete, Greece
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 15 (20240220), s. 1344878
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38444844 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155717 $b ABA008
999    __
$a ok $b bmc $g 2081219 $s 1216851
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 15 $c - $d 1344878 $e 20240220 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace